Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.650 -0.160 (-5.69%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Via Investor Brand Network
Annovis to Attend the AAIC 2025 with Four Poster Presentations
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
Via Investor Brand Network
Topics Regulatory Compliance
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes
Via Investor Brand Network
Study Uncovers Link Between Gut Infection and Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
Via Investor Brand Network
Annovis to Host Webinar and Live Q&A on June 24, 2025
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
Via Investor Brand Network
Topics Intellectual Property
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
Via Investor Brand Network
Annovis Bio Appoints Hui Liu as Director of Biostatistics
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
Via Investor Brand Network
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
Via Investor Brand Network
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
Via Investor Brand Network
Topics Intellectual Property
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
The Brain’s ‘Cleanup Crew’ Could Hold the Key to Alzheimer’s Treatment, Study Shows
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit
Via Investor Brand Network
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
From Annovis Bio Inc.
Via GlobeNewswire
Scientists Say Brain Stimulations Hold Potential in Treating Anxiety in Parkinson’s Sufferers
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering
Via Investor Brand Network
US Announces Plan to Combat Parkinson’s Disease Across the Country
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.